Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy

The myeloid tumor suppressor KMT2C is recurrently deleted in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), particularly therapy-related MDS/AML (t-MDS/t-AML), as part of larger chromosome 7 deletions. Here, we show that KMT2C deletions convey a selective advantage to hematopoietic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ran, Okeyo-Owuor, Theresa, Patel, Riddhi M., Casey, Emily B., Cluster, Andrew S., Yang, Wei, Magee, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951951/
https://www.ncbi.nlm.nih.gov/pubmed/33596429
http://dx.doi.org/10.1016/j.celrep.2021.108751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951951/
https://www.ncbi.nlm.nih.gov/pubmed/33596429
http://dx.doi.org/10.1016/j.celrep.2021.108751

Ejemplares similares